Keros Capital Lease Obligations from 2010 to 2024
| KROS Stock | USD 56.58 0.66 1.18% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 14.4 M | Current Value 15.2 M | Quarterly Volatility 5.6 M |
Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 7.3 K, Dividend Yield of 0.0 or PTB Ratio of 3.35. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
Keros | Capital Lease Obligations |
Latest Keros Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Keros Therapeutics over the last few years. Keros Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Keros Therapeutics asset purchases. For example, Keros Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Keros Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Keros Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Keros Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Keros Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 3,549,013 | |
| Geometric Mean | 1,497,368 | |
| Coefficient Of Variation | 157.05 | |
| Mean Deviation | 4,297,221 | |
| Median | 788,000 | |
| Standard Deviation | 5,573,624 | |
| Sample Variance | 31.1T | |
| Range | 14.4M | |
| R-Value | 0.71 | |
| Mean Square Error | 16.6T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 883,930 | |
| Total Sum of Squares | 434.9T |
Keros Capital Lease Obligations History
About Keros Therapeutics Financial Statements
Keros Therapeutics shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 14.4 M | 15.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.